Ocumetics Technology amends private placement terms

Executive Summary

• Ocumetics Technology Corp. has amended the terms of its brokered private placement led by Centurion One Capital Corp.
• The amended offering increases the issue price to 60 cents per unit and raises the aggregate gross proceeds to up to $2.5 million.
• The offering includes a 15% over-allotment option for the lead agent, potentially increasing total gross proceeds by an additional $375,000.

Key Details

• Amended Issue Price: 60 cents per unit.
• Base Offering Size: Up to 4,166,666 units.
• Base Gross Proceeds: Up to $2.5 million.
• Unit Composition: Each unit consists of one common share and one common share purchase warrant.
• Warrant Terms: Each warrant entitles the holder to acquire one common share at an exercise price of 75 cents per share.
• Warrant Expiry: Three years following the closing date.
• Over-Allotment Option: The lead agent has an option to purchase up to an additional 625,000 units at the amended issue price.
• Additional Gross Proceeds from Option: Up to $375,000.
• Option Expiry: Exercisable in whole or in part up to two business days prior to the closing date.
• Use of Proceeds: Financing first-in-human clinical trials, continuing research and development, and general corporate purposes.
• Expected Closing Date: On or around December 29, 2025.
• Regulatory Conditions: Subject to receipt of all necessary approvals, including the TSX Venture Exchange.
• Insider Participation: Anticipated participation by insiders, lead agent, and affiliates; exempt from formal valuation and minority shareholder approval requirements under MI 61-101 as consideration is not expected to exceed 25% of market capitalization.
• Jurisdictions: Offered in British Columbia, Alberta, Ontario, the United States, and other mutually agreed jurisdictions.
• Hold Period: No statutory hold period applies to securities issued under the listed issuer financing exemption.

Notable Quotes

• None provided in the text.